Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-CRM Vaccine Safety and Immunogenicity in Adolescents
NCT00262041Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2004
- Primary completion
- Mar 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen in meningococcal disease (3 arms), sponsored by Novartis. Primary endpoint: Percentages of Subjects With N.Meningitidis Human Serum Bactericidal Activity (hSBA) Titers ≥ 1:4 at 1 month. Started Oct 2004; status: completed.
02
Drugs
neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00262041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262041.